Related by context. All words. (Click for frequent words.) 71 retrospective cohort study 70 multicentre prospective 70 longitudinal cohort study 68 prospective observational 68 retrospective cohort 67 longitudinal observational study 67 prospective longitudinal 67 prospective cohort 67 substudy 66 prospective nonrandomized 66 prospective observational cohort 66 prospective multicentre 66 LHRH receptor positive 66 retrospective observational study 65 retrospectively analyzed 65 TAXUS ARRIVE 65 randomized multicenter trial 64 Multi Ethnic Study 64 multicenter randomized controlled 64 NSABP B 64 Carotid Revascularization Endarterectomy vs. 64 placebo controlled dose escalation 64 meta regression 64 Framingham Offspring 64 susceptibility loci 63 multicentre study 63 Screening Trial 63 CaPSURE 63 Intervention Trial 63 Wisconsin Sleep Cohort 63 multicenter phase 63 Digital Mammographic Imaging 63 transrectal ultrasound guided 63 multicenter study 63 multiple logistic regression 63 prospective multicenter study 63 Multicenter 63 CALGB 62 metaanalysis 62 efficacy evaluable 62 multicenter Phase II 62 logistic regression analysis 62 IPAH 62 multicenter randomized placebo controlled 62 Clinical Antipsychotic Trials 62 REALITY Trial 62 relapsed MM 62 observational cohort 62 Prostate Lung Colorectal 62 metastatic neuroendocrine tumors 62 prospectively randomized 62 PCI ExTRACT TIMI 62 patientswith 62 subanalysis 62 limiting generalizability 62 multicenter prospective 62 Patient Registry 62 clinicopathologic 62 Randomized controlled 62 liver transplant recipients 62 psychiatric outpatients 62 Multicenter AIDS 62 multicentre randomized 62 phase IIIb 62 CHAMPION PCI 61 placebo controlled clinical 61 HORIZONS AMI trial 61 tumor histology 61 multicenter randomized clinical 61 Multiethnic Study 61 ExTRACT TIMI 61 angiographically 61 randomized blinded 61 Phase IIIb study 61 RE LY ® 61 florbetaben 61 logistic regression analyzes 61 Observational Study 61 underwent resection 61 histological subtype 61 Subgroup analysis 61 multivariate analyzes 61 BPS IC 61 PLCO 61 Lewy bodies DLB 61 randomized controlled trials RCTs 61 null responder 61 CARDIA 61 Sipuleucel T 61 Multivariate logistic regression 61 ENDEAVOR IV 61 HCV SPRINT 61 Normative Aging Study 61 Univariate analysis 61 clinico pathological 60 Group RTOG 60 treatment naive genotype 60 Current Controlled Trials 60 multicentre randomized double 60 prospective multicenter 60 Multiple logistic regression 60 Degarelix 60 CARDIA study 60 RE LY trial 60 longitudinal study 60 prostate cancer CaP 60 Logistic regression 60 duplex ultrasonography 60 CIMZIA TM certolizumab pegol 60 KRAS mutations occur 60 Sprague Dawley rats 60 Systemic Sclerosis 60 double blinded randomized 60 congenital toxoplasmosis 60 nodal metastasis 60 randomized multicenter 60 ANCOVA 60 NHAMCS 60 operable breast cancer 60 Phase III randomized controlled 60 HYVET 60 pretreatment serum 60 bivariate analyzes 60 BR.# 60 prospective randomized multicenter 60 Multicentre 60 NMIBC 60 PARTNER Trial 60 Clinicaltrials.gov 60 Randomized Evaluation 60 Sociodemographic 60 blinded randomized placebo controlled 60 Histologic 59 multivariate logistic regression 59 acute myeloid 59 histologically proven 59 ILLUSTRATE 59 Atherosclerosis Risk 59 PREVENT IV 59 CAMMS# 59 PROactive study 59 biliary tract cancer 59 randomized multicenter Phase III 59 clinicopathological 59 TNM staging 59 multicenter multinational 59 Multivariate analysis 59 NAMCS 59 urolithiasis 59 Screening Trial DMIST 59 Angiographic 59 multivariable analysis 59 conditional logistic regression 59 Prospective Randomized 59 TAXUS V 59 anthropometric measurements 59 number NCT# ClinicalTrials.gov 59 genotypic resistance 59 randomized Phase IIb 59 FDG-PET/CT 59 genomic biomarker 59 multicentric 59 Health Initiative Observational 59 SWOG 59 logistic regression model 59 Edge STudy 59 underwent CABG 59 BRCA mutation carriers 59 extramedullary 59 GH deficiency 59 visceral metastases 59 randomized multicentre 59 nonmetastatic 59 susceptibility locus 59 p# biomarker 59 prostate cancer PCa 59 Cohort Study 59 multivariable analyzes 59 Echocardiographic 59 pharmacokinetic pharmacodynamic 59 null responder HCV 59 HIV seropositive 59 Renal Cell Carcinoma RCC 59 HeFT 59 prognostic variables 59 neoadjuvant treatment 59 underwent liver transplantation 59 Acute Decompensated Heart Failure 59 Coronary Artery Bypass Graft 59 phase IIb study 59 BARI 2D 59 Histopathological 59 EuroSCORE 59 SPIRIT FIRST 59 Kaplan Meier analysis 59 basal bolus regimen 59 underwent radical prostatectomy 58 ER CHOP 58 Cardiac Allograft Rejection 58 multicentre 58 Neuroepidemiology 58 pharmacokinetics PK 58 ENGAGE AF TIMI 58 #F FDG PET 58 pT2 58 CARE HF 58 Ovarian PLCO Cancer 58 genomewide association study 58 nulliparous women 58 randomized crossover 58 Systemic Lupus Erythematosus SLE 58 Estrogen Receptor 58 GPRD 58 T1DM 58 prospectively defined 58 diabetes mellitus DM 58 metaplasia 58 Poisson regression 58 Injury Severity Score 58 ConclusionThis 58 Evaluation WISE 58 REVIVE Diabetes 58 histologically confirmed 58 undergone radical prostatectomy 58 prospective randomized controlled 58 Trandolapril 58 papillary renal cell carcinoma 58 multicenter trials 58 HIV seroconversion 58 antiretroviral naïve 58 clinically evaluable 58 F FDG PET 58 polyarticular 58 overnight polysomnography 58 Framingham Offspring Study 58 Women Ischemia Syndrome 58 histopathologic diagnosis 58 clinical pharmacology studies 58 EBUS FNA 58 Vertos II 58 TG MV 58 miRview ™ mets 58 Adjuvant therapy 58 SORT OUT III 58 Comorbidity 58 cytologic 58 multicenter placebo controlled 58 abacavir Ziagen 58 SYNTAX trial 58 prelicensure 58 Swedish Mammography Cohort 58 SF #v# 58 Histological 58 Randomized Study 58 conducted retrospective cohort 58 Atherosclerosis MESA 58 Histopathologic 58 EINSTEIN DVT 58 ductal adenocarcinoma 58 serum lipid levels 58 rFSH 58 NCCTG 58 Communities ARIC Study 58 undergoing coronary angiography 58 nonrandomized 58 ug dose 58 hemodialysis patients 58 STEP BD 58 Infarct 58 GAMMAGARD 58 prospective observational studies 58 suicide attempters 58 germline mutations 58 diagnostic biomarker 58 engineered urethras 58 TAXUS VI 58 METHODS 58 hematological relapse 58 STRIDE PD 58 Acute Coronary Syndromes ACS 58 multivariate Cox 58 SEER database 58 epoetin alpha 58 variant rs# 58 urothelial carcinoma 58 DNA methylation markers 58 Phase III ThermoDox 58 RCW breast cancer 58 pretransplant 58 cardiac perfusion 58 randomized blinded placebo 58 Prospective Multicenter 58 prognostic indicators 58 multicenter randomized double 58 univariate analyzes 58 Feasibility Trial 58 PK PD modeling 58 Cardiotoxicity 58 EURIDIS 58 ENESTnd 58 placebo controlled Phase III 58 VADT 58 breast carcinoma 58 Enzastaurin 57 idiopathic pulmonary arterial hypertension 57 BERKELEY CA UroToday.com 57 ASCUS 57 HIV seronegative 57 IMPACT DCM 57 Aggressive Reduction 57 FDG PET imaging 57 metabolomic profiles 57 BCIRG 57 opioid dependent 57 Dr. Kandzari 57 ZACTIMA 57 recurrent malignant glioma 57 etiologic 57 CURRENT OASIS 7 57 OLYMPIA registry 57 T2DM 57 genomewide 57 blinded randomized controlled 57 BRIM3 57 % CI #.#-#.# [003] 57 mean ± SEM 57 preclinical efficacy 57 ROCKET AF 57 CRLX# 57 undetectable HBV DNA 57 pharmacokinetic PK 57 Patency 57 KRAS gene mutations 57 prospectively evaluated 57 mITT population 57 Main Outcome Measure 57 Genetics Consortium 57 vesicoureteral reflux VUR 57 bowel capsule endoscopy 57 undergoing radical cystectomy 57 randomized Phase 2b 57 deCODE AF TM 57 undergone hysterectomies 57 carotid artery stenting CAS 57 clinically localized prostate 57 WTCCC 57 demyelinating 57 radical retropubic prostatectomy 57 randomized controlled clinical 57 stratifying patients 57 bladder carcinoma 57 multicenter 57 Antiviral Therapy 57 transcranial Doppler ultrasound 57 treatment naïve genotype 57 LUX Lung 57 LNG IUS 57 adenotonsillectomy 57 Intervention Effectiveness 57 polycythemia vera essential thrombocythemia 57 randomized controlled trial 57 NSCLC tumors 57 pain palliation 57 WHIMS 57 CYP#D# inhibitor 57 Prognostic factors 57 AIR2 Trial 57 osteoporotic vertebral compression fractures 57 prospectively enrolled 57 PDE# inhibitors 57 NCT# ClinicalTrials.gov 57 leiomyomas 57 ACUITY trial 57 murine models 57 echocardiographic parameters 57 Study ARIC 57 randomized controlled multicenter 57 Phase IIIb clinical 57 Venous thromboembolism 57 HealthGrades analyzed 57 Birth Cohort 57 quadrivalent HPV vaccine 57 de novo AML 57 GOUT 57 nomogram 57 Logistic regression analysis 57 NOX E# 57 transvaginal sonography 57 registrational Phase 57 NATRECOR ® 57 Optical Coherence Tomography 57 CC genotype 57 TEMSO 57 System USRDS 57 HORIZONS AMI 57 randomized discontinuation 57 Non Alcoholic Steatohepatitis 57 Intervention Trial GAIT 57 abnormal cytology 57 MR spectroscopy 57 Myocardial Infarction Study 57 Univariate 57 MTWA testing 57 multivessel coronary artery 57 EchoCRT 57 ELCAP 57 Phase IIIB IV 57 phase IIa clinical 57 crizotinib PF # 57 Randomized Controlled 57 HER2 expression 57 gene expression profiles 57 Marketrack 57 randomized Phase III 57 differential gene expression 57 Methods Retrospective 57 REGARDS 57 differentiate squamous 57 zotarolimus eluting stent 57 DMIST 57 ragweed allergic 57 haplotype map 57 ECASS 57 Phase Ib IIa clinical 57 Afib 57 periprocedural MI 57 subgroup analyzes 57 debulking surgery 57 Phase 1a clinical 57 immunohistochemical 57 fluorodeoxyglucose positron emission tomography 57 MAGE A3 ASCI 57 HIV uninfected 57 thetreatment 57 estimated GFR 57 nondiabetic patients 57 thyroidectomy 57 DAPT Study 57 surgically resected 57 nonmetastatic prostate cancer 57 posttransplant 57 Doppler echocardiography 57 binary logistic regression 57 MADIT II 57 liver transplantations 57 Preoperatively 57 endoscopic ultrasonography 57 Phase Ib clinical 57 CORE OM 57 logistic regression models 57 dyslipidaemia 57 multicenter clinical 57 neurocognitive impairment 57 Juvenile Idiopathic Arthritis 57 BRIM2 57 Evaluable 57 multivariable Cox 57 Intervention Effectiveness CATIE 57 Fracture Intervention Trial 57 atherothrombosis 57 recurrent endometrial cancer 57 Chronic lymphocytic leukemia 57 Nonalcoholic Fatty Liver Disease 56 ToGA 56 Tumor Response 56 Aspergillus nidulans 56 CATIE AD 56 pulmonary metastasis 56 Skin sterol 56 Surgical Treatment 56 prognostic biomarker 56 atherothrombotic disease 56 C. trachomatis 56 pancreatic adenocarcinoma 56 SEER registry 56 HIV HCV coinfected 56 renal cortical 56 PROSTVAC ® 56 Prostate Px + 56 Schizophrenia Bulletin 56 gadolinium enhanced 56 BOLDER II 56 adjuvant tamoxifen 56 genitourinary cancers 56 DAS# CRP 56 Pertuzumab 56 LUMINATE 56 PROLARIS 56 Netherlands Cohort Study 56 multivariable logistic regression 56 mg administered orally 56 IMPROVE HF 56 NOD mouse 56 e HEALING 56 angiography CCTA 56 controlled multicenter 56 Regression analyzes 56 HeFH 56 Severe Asthma 56 Abstract P# [002] 56 Cell Lymphoma 56 multicenter Phase III 56 chest radiographs 56 miglustat 56 AGHD 56 Chronic Heart Failure 56 observational study 56 Cloretazine 56 study1 56 immunohistochemical staining 56 recurrent glioblastoma multiforme 56 genetic variants associated 56 ductal carcinomas 56 NICE SUGAR 56 breast cancer subtypes 56 resected pancreatic cancer 56 FDG PET CT 56 oral squamous cell 56 familial aggregation 56 thyroid carcinoma 56 NCDB 56 chromosome #p# [002] 56 CLIRS 56 Phase Ib II 56 Symptom severity 56 trials RCTs 56 iniparib BSI 56 RARP 56 Liver biopsies 56 corticosteroid induced 56 Phase IIIb 56 Arch Intern Med 56 RE LY 56 Ovarian Cancer Screening 56 ImmuKnow assay 56 NIDDM 56 Safinamide 56 obese postmenopausal 56 Multiethnic Cohort Study 56 Helicobacter pylori eradication 56 Val HeFT 56 PERSEUS clinical program 56 HIV coinfected 56 Genotypic 56 ID NCT# 56 VATS lobectomy 56 pressure monitoring ABPM 56 REVEAL Registry 56 miRview ™ squamous 56 Mantel Haenszel 56 Decompensated Heart Failure 56 pharmacokinetic PK study 56 ICSI cycles 56 CIN2 + 56 proton MR spectroscopy 56 Phase III randomized 56 Thromboembolism 56 PD2i R 56 vivo preclinical 56 transthyretin amyloidosis 56 COR Analyzer 56 PRECiSE 56 oncologic outcomes 56 hematopoietic cancers 56 renal tumors 56 reflux esophagitis 56 causative mutation 56 core needle biopsies 56 placebo controlled trials 56 GBA mutations 56 phase IIb trial 56 perinatal outcomes 56 Parathyroid Hormone 56 COPERNICUS 56 etiologic factors 56 Dialysis Outcomes 56 Multivariate analyzes 56 epithelial ovarian 56 posttreatment 56 ELBW infants 56 proband 56 advanced neoplasia 56 histopathological 56 hMG 56 ultrasonographic examination 56 microalbumin 56 ASCO abstract 56 prostate carcinoma 56 C#BL 6 mice 56 Microarray analysis 56 biochemical relapse 56 multicenter clinical trials 56 budesonide foam 56 transplantation HSCT 56 Hepatotoxicity 56 physicians podiatrists 56 brivanib 56 multicenter randomized 56 narcolepsy cataplexy 56 dietary questionnaires 56 Heavy menstrual bleeding 56 Young Adults CARDIA 56 Multicenter Study 56 Heterozygous Familial Hypercholesterolemia 56 sacral neuromodulation 56 hemodynamically significant 56 relapsing remitting MS RRMS 56 genetic loci 56 diagnostic coronary angiography 56 APOE genotype 56 Alequel 56 proliferative retinopathy 56 HPTN 56 Unstable Angina 56 RezularTM 56 virological response 56 Computed tomographic 56 intratympanic 56 blind randomized controlled 56 S. maltophilia 56 MVA MUC1 IL2 56 solithromycin 56 Electroencephalography 56 Cytogenetic 56 antiangiogenic agent 56 MenACWY 56 J Clin Oncol 56 urologic surgeons 56 pharmacodynamic PD 56 heFH 56 landmark ATHENA 56 Surgical resection 56 NuroPro PD 56 randomized clinical 56 ovariectomized 56 J Nutr 56 pediatric acute lymphoblastic 56 galiximab 56 pharmacokinetic pharmacodynamic PK PD 56 refractory metastatic 56 Nexrutine 56 randomizing patients 56 seropositivity 56 histologic diagnosis 56 APEX AMI trial 56 MGd 56 adjuvant cisplatin 56 paclitaxel eluting stents 56 renal biopsy 56 Phase Ib study 56 squamous cell lung cancer 56 Meta analyzes 56 intradermal injections 56 Subtypes 56 KRAS mutation 56 % CI #.#-#.# [008] 56 acetabular fractures 56 diagnostic angiography 56 ACOSOG Z# 56 gefitinib Iressa 56 Risk Stratification 56 Radiographic 56 recurrent metastatic 56 OPT CHF 56 Treatment Outcome 56 FDG PET scans 56 laparoscopic radical nephrectomy 55 CAPRIE 55 peripartum 55 Radiation Therapy Oncology 55 trial evaluating PRX# 55 T1a 55 EEG recordings 55 OvaRex MAb 55 retrospectively reviewed 55 NSTE ACS 55 TAXUS ATLAS 55 VTE prophylaxis 55 postintervention 55 receptor tyrosine kinase inhibitor 55 AFREZZA TM 55 Acute Coronary Syndromes 55 scintigraphic 55 rALLy trial 55 pharmacodynamic profiles 55 Coronary CTA 55 HCV RESPOND 2 55 Tyrosine Kinase Inhibitors 55 differentially expressed proteins 55 ErbB2 positive 55 histologic subtype 55 Left Ventricular Dysfunction 55 RECORD1 55 hip BMD 55 antiretroviral naive 55 relapsed refractory AML 55 mild cognitive impairments 55 Sequencing Systems 55 PSMA ADC 55 Communities ARIC study 55 perfusion CT 55 Oncotype DX Recurrence Score 55 lymphoproliferative disorders 55 Cholesterol Levels SPARCL 55 uricase 55 Ozarelix 55 Tumor Registry 55 somatostatin analog 55 Treat Parkinson Disease 55 bivariate 55 Kaplan Meier curves 55 Baltimore Longitudinal Study 55 TAXUS IV 55 Stenting Trial CREST 55 NABTT 55 RRMS patients 55 liver biopsies 55 juvenile idiopathic arthritis 55 NHANES III 55 comorbid depression 55 Biodesix 55 R roscovitine 55 Hp2 2 55 docetaxel cisplatin 55 huN# DM1 55 #-# Full Text 55 Clinical Outcome 55 Myelodysplastic syndromes MDS 55 Gynecologic Oncology Group 55 Phase #/#a 55 euthymic patients 55 cerebral microbleeds 55 AIR CF1 55 authors hypothesized 55 microsatellite instability 55 urothelial cancer 55 Comorbidities 55 pimecrolimus cream 55 Sequenced Treatment Alternatives 55 guideline concordant 55 comorbid psychiatric disorders 55 Quinamed 55 Complications Trial 55 Temsirolimus 55 Medullary thyroid cancer 55 Prostate Disease 55 Therapeutic Advances 55 cytoreductive nephrectomy 55 PEG IFN 55 recurrent glioma 55 SEER registries 55 PITX2 55 tumor subtypes 55 Familial Hypercholesterolemia 55 toenail onychomycosis 55 androgen suppression 55 prepubertal 55 EORTC 55 osteopenic 55 Tomographic 55 resectable pancreatic cancer 55 Proellex TM 55 Interpersonal Psychotherapy 55 desvenlafaxine succinate 55 genes differentially expressed 55 neratinib 55 cDNA microarray 55 nonpregnant women 55 dose escalation phase 55 pigmented skin lesions 55 unstable angina pectoris 55 precancerous cervical 55 eculizumab therapy 55 rALLy clinical trial 55 Hemodialysis Patients 55 placebo controlled randomized 55 computed tomographic 55 baseline FEV 55 prucalopride 55 Genetic Markers 55 Collaborative Perinatal Project 55 LV dysfunction 55 Reynolds Risk Score 55 gene polymorphism 55 plasma pharmacokinetics 55 MELAS 55 distinct subtypes 55 sacral nerve stimulation 55 #:# -# [003] 55 randomized controlled Phase 55 male Sprague Dawley 55 ADAGIO study 55 smoldering myeloma 55 Lymph node 55 Nesiritide 55 Adenomas 55 adnexal mass 55 refractory anaplastic astrocytoma 55 Pooled Analysis 55 Kaplan Meier estimate 55 Trofex 55 CYP#D# genotype 55 Phase 1b trial 55 ChronVac C R 55 Electrophysiological 55 ABCSG 55 EDEMA3 55 pharmacogenetic testing 55 histologic findings 55 Kruskal Wallis test 55 thrombophilia 55 REACH Registry 55 urodynamic 55 PICSO ® 55 patients undergoing CABG 55 SABCS 55 vitespen 55 adjuvant endocrine therapy 55 Retreatment 55 Neuropsychiatric Inventory NPI 55 sociodemographic characteristics 55 chronic myocardial ischemia 55 pharmacodynamic effects 55 CIBIC plus 55 SNP rs# [002] 55 differentially expressed genes 55 Neoadjuvant 55 MDQ 55 endoscopic retrograde cholangiopancreatography ERCGrant Parpan 55 Thrombolysis 55 viral kinetic 55 Phase IIb III 55 odds ratios ORs 55 lorcaserin Phase 55 Hypertrophy 55 #:#-# [031] 55 IDH1 mutation 55 clinically asymptomatic 55 chemoprevention trials 55 MEND CABG 55 ACCOMPLISH 55 microarray experiments 55 davunetide intranasal AL 55 NSABP 55 Phase Ib Clinical Trial 55 melphalan prednisone 55 HDL Selective Delipidation 55 peptic ulcer bleeding 55 fetal echocardiography 55 phenotyping 55 LVNC 55 Clostridium difficile Infection 55 Lp PLA 2 55 phylogenetic analyzes 55 randomized controlled 55 Preclinical Study 55 hip resurfacing arthroplasty 55 postmenopausal osteoporotic women 55 immunocompetent 55 Acute Myocardial Infarction 55 CSF biomarkers 55 Pharmacokinetics PK 55 Diabetes Interventions 55 EQ 5D 55 aged ≥ 55 BARACLUDE ® 55 karyotypes 55 neoadjuvant 55 Pre RELAX AHF 55 multivariate regression analysis 55 metastatic malignant 55 ASTEROID 55 chronic thromboembolic pulmonary 55 femoral neck fracture 55 underwent surgical resection 55 Hepatocellular Carcinoma HCC 55 K ras mutations 55 End Results SEER 55 Randomized Controlled Trial 55 IMiDs ® compound 55 RSD# oral 55 BMI z 55 Ann Intern Med 55 Bacteremia 55 ABSORB trial 55 liver resection 55 serum estradiol 55 Kahalalide F 55 ANCHOR trial 55 ORACLE MS 55 SSc 55 double blinded placebo 55 Subgroup analyzes 55 supratentorial 55 mutated K ras 55 NGFN 55 CLARITY study 55 MDCT scans 55 myocardial viability 55 HER2 overexpression 55 Breast Carcinoma 55 #:#-# [029] 55 primary hyperparathyroidism 55 XIENCE V Stent System 55 ACS NSQIP 55 PreDx DRS 55 digital subtraction angiography 55 bone scintigraphy 55 Xelox 54 Hodgkin lymphoma HL 54 adenomatous 54 LRTI 54 THIS STUDY 54 Immunohistochemical analysis 54 PIB PET 54 TF CBT 54 Naive Patients 54 VITAL Trial 54 definite stent thrombosis 54 allogeneic HSCT 54 HSCT 54 cerebral oximetry 54 serum selenium 54 autologous SCT 54 hepatectomy 54 atherogenic dyslipidemia 54 AVOREN 54 #:#-# [033] 54 prospective multicenter randomized 54 AIR CF3 54 GW# [003] 54 FDG PET 54 Adverse Event 54 ALSYMPCA 54 baseline LDH 54 neurosensory 54 haematological cancers 54 Cohort Study MACS 54 Prostate Cancer Prevention 54 GEM OS1 54 PRESEPT 54 morphometric 54 Angiox R 54 hematological parameters 54 Cardiorespiratory fitness 54 Myeloproliferative Neoplasms 54 Acute Ischemic Stroke 54 warfarin dosage 54 Lancet Oncology journal 54 plus DOXIL 54 RTOG 54 Blinatumomab 54 DF HCC 54 tumor subtype 54 ascending dose 54 mammographic density 54 Pregnancy Registry 54 pretest probability 54 Serdolect ® 54 KRAS status 54 CYPHER Stent 54 portal vein thrombosis 54 peginterferon alpha 54 univariate 54 vulvovaginal atrophy 54 plasma kallikrein 54 autosomal 54 Aneurysm Repair 54 symptomatic BPH 54 non valvular atrial 54 ENDEAVOR III 54 microsatellite markers 54 randomized placebo controlled 54 SPECT CT imaging 54 blinded randomized 54 PET CT scanning 54 RCTs 54 EOquin TM 54 XIENCE V PROMUS Stent 54 descending thoracic 54 prospective randomized placebo 54 SNP rs# [001] 54 Interview Survey CHIS 54 thromboprophylaxis 54 Acute myocardial infarction 54 Cohort Consortium 54 Critical Limb Ischemia CLI 54 NMES 54 pharmacodynamic properties 54 practitioners internists 54 achieved sustained virological 54 NeuroStar TMS Therapy 54 PiB PET 54 Accelerated Partial Breast Irradiation 54 spontaneous regression 54 riociguat 54 refractory prostate cancer 54 thoracoscopic lobectomy 54 ICON7